UroGen Pharma Ltd. Interest Income (Expense), Net
UroGen Pharma Ltd. (URGN) reported Interest Income (Expense), Net of $3.61 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2019-11-12
- UroGen Pharma Ltd. interest income (expense), net for the quarter ending 2019-09-30 was $1.26M, a 164.63% increase year-over-year.
- UroGen Pharma Ltd. interest income (expense), net for the quarter ending 2018-09-30 was $475.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month |
|---|---|---|---|
| 2019-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.61M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.35M 10-Q · filed 2019-08-09 | ||
| 2018-09-30 | $475.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.39M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $911.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |